This study investigates the treatment of non-muscle invasive bladder cancer. The purpose of this study is to explore the barriers and facilitators affecting treatment compliance and to test a Bacillus Calmette-Guerin (BCG) at-home program. Participants will be divided into two study arms: one focusing on understanding treatment compliance and the other testing the home-based BCG treatment program.

Participants in the second study arm will receive BCG treatment at home and will use a conversational agent. This agent will help measure their symptoms, quality of life, and improve their ability to manage their own health. The study will collect information to better understand how patients manage their treatment and any challenges they face.

• Who can participate: Adults aged 18 years or older who have completed intravesical treatment for non-muscle invasive bladder cancer within the past year or who have been diagnosed with the condition and prescribed BCG for initial therapy can participate. Key stakeholders with over 2 years of experience in BCG delivery are also eligible.
• Study details: Participants will either engage in discussions to identify barriers to treatment or receive investigational BCG therapy at home while using a conversational agent to report symptoms and quality of life.